Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infections

about

Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infections

Item

http://www.wikidata.org/entity/Q36960592

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Short-term treatment outcomes ...... epatitis B virus co-infections

@en

type

Item

label

Short-term treatment outcomes ...... epatitis B virus co-infections

@en

prefLabel

Short-term treatment outcomes ...... epatitis B virus co-infections

@en

P1476

Short-term treatment outcomes ...... epatitis B virus co-infections

@en

P2093

Afrakoma Adjoa Agyei

http://www.w3.org/2001/XMLSchema#string

Francesca Ziga

http://www.w3.org/2001/XMLSchema#string

Julius Abraham Addo Mingle

http://www.w3.org/2001/XMLSchema#string

Kwamena William Coleman Sagoe

http://www.w3.org/2001/XMLSchema#string

Margaret Lartey

http://www.w3.org/2001/XMLSchema#string

Max Arens

http://www.w3.org/2001/XMLSchema#string

Theophilus Korku Adiku

http://www.w3.org/2001/XMLSchema#string

P2860

Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda

HIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in Ghana

Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in Sub-Saharan Africa

HIV outcomes in Hepatitis B virus coinfected individuals on HAART

Detection of highly prevalent hepatitis B virus coinfection among HIV-seropositive persons in Ghana.

Hepatitis B virus X gene activates kappa B-like enhancer sequences in the long terminal repeat of human immunodeficiency virus 1.

The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.

A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria

Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV inf

Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort

P2888

s12941-016-0152-2

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12941-016-0152-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kwabena Duedu

P577

2016-06-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1052500172

http://www.w3.org/2001/XMLSchema#string

P698

27251610

http://www.w3.org/2001/XMLSchema#string

P932

4890471

http://www.w3.org/2001/XMLSchema#string